Livogard Tablet is a pharmaceutical formulation containing L-Ornithine L-Aspartate (150 mg) and Pancreatin (100 mg), designed to support hepatic function and improve digestive enzyme activity. L-Ornithine L-Aspartate is an amino acid compound that facilitates ammonia detoxification by enhancing the urea cycle in the liver, thereby reducing blood ammonia levels commonly elevated in hepatic encephalopathy and other liver dysfunctions. Pancreatin, a mixture of digestive enzymes including amylase, lipase, and protease, aids in the breakdown of carbohydrates, fats, and proteins, improving nutrient absorption and alleviating symptoms associated with pancreatic insufficiency such as malabsorption, steatorrhea, and indigestion. Livogard Tablet is indicated for the management of chronic liver diseases, hepatic encephalopathy, and exocrine pancreatic insufficiency. It may be used as an adjunct therapy to restore normal metabolic functions and enhance digestive efficiency. The combination of these active ingredients provides a synergistic effect, promoting liver detoxification while supporting pancreatic enzyme supplementation. Livogard should be administered under medical supervision, with dosage adjusted according to the severity of the condition and patient response. Caution is advised in patients with hypersensitivity to any component or severe renal impairment.